Enovis CORP (ENOV) Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Industry: Medical - Devices
Enovis Corporation NYSE:ENOV Healthcare · Medical - Devices
Mkt Cap $1.15B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
PRISM MarketView Highlights Five Innovative Public Companies Supporting Strength and Mobility for National Physical Therapy Month
PRISM MarketView published a National Physical Therapy Month feature naming Enovis among five public companies supporting strength and mobility.
The piece highlights Enovis' Prevention & Recovery business and cites previously reported second-quarter net sales of $583 million, up 5% organically.
The release is promotional media coverage from a third-party platform, not a company disclosure; no new financial or operational information about Enovis is announced.
• 10d ago AI analysis › Press Release
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Enovis will host a conference call and webcast to discuss third quarter 2026 results on Thursday, November 5th, 2026 at 8:30 a.m. ET, with the earnings press release issued earlier that morning.
The webcast and presentation will be available in the Investors section of the Enovis website, with a replay posted later that day.
No financial results are disclosed in this announcement; it is solely a scheduling and access notice for investors.
• 24d ago AI analysis › Press Release
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah SA (Nasdaq/Euronext: NYXH) appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman after seven years at the helm.
Kelly was Chairman, President and CEO of Teleflex until January 2026 and currently serves on the board of Enovis Corporation (NYSE: ENOV), bringing more than 25 years of MedTech leadership experience.
The move underscores Nyxoah's shift to a US-focused commercial organization following August 2025 FDA approval and the early-stage launch of its Genio neuromodulation therapy for obstructive sleep apnea.
For Enovis, the news is contextual: its director takes a full-time CEO role elsewhere, which investors may monitor for board-commitment implications.
• 1mo ago AI analysis › Press Release ⚠ 2
REG-Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah (Euronext Brussels/Nasdaq: NYXH) appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman.
Kelly led Teleflex (NYSE: TFX) as President and CEO from January 2018 and as Chairman from May 2020 until January 2026, and currently serves as a director of Enovis Corporation (NYSE: ENOV) — the connection to the ENOV ticker in this filing.
The move signals Nyxoah's pivot to a US-focused commercial strategy following the August 2025 FDA approval and early-stage US launch of its Genio neuromodulation system for obstructive sleep apnea.
• 1mo ago AI analysis › Press Release
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Enovis has become the first industry partner to sponsor multiple AAOS registries, adding the Shoulder & Elbow Registry (SER) to its longtime American Joint Replacement Registry sponsorship through 2027.
CEO Damien McDonald framed the deal as reinforcing Enovis' commitment to evidence generation, particularly around outcomes in shoulder arthroplasty.
The sponsorship carries no disclosed financial terms and is unlikely to move fundamentals, but it supports Enovis' clinical-evidence positioning in orthopaedics.
• 1mo ago AI analysis › Press Release ● Major
eCential Robotics Announces Binding Offer from Enovis
Enovis has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics and navigation solutions. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals and completion of the French works council consultation process.
The acquisition will integrate eCential's FDA 510(k)-cleared Op.n platform into Enovis' ASTRA enabling technology ecosystem. This addition provides robotic automation capabilities that complement Enovis' existing ARVIS Augmented Reality System.
Management emphasized that the acquisition accelerates the innovation roadmap and expands the surgical robotics portfolio to improve precision and workflow efficiency for surgeons.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Enovis signed a binding offer to acquire eCential Robotics for an upfront enterprise value of €155 million, adding robotic automation capabilities to its ASTRA enabling technology platform.
The transaction includes approximately €176 million in cash consideration at closing, with up to €35 million in contingent payments, and is expected to close by year-end 2026 pending regulatory approvals.
Enovis anticipates 150 basis points of adjusted EBITDA margin dilution in 2027 due to deal costs, but expects free cash flow conversion to increase to 50%, exceeding $100 million.
• 2mo ago AI analysis › Press Release
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Enovis announced its participation in the 2026 Wells Fargo HealthCare conference, scheduled to take place on Tuesday, September 8, 2026, at the Encore Boston Harbor.
CEO Damien McDonald and CFO Ben Berry are set to participate in a fireside chat session beginning at 1:30 p.m. Eastern Time.
Investors can access a live audio webcast of the session as well as a replay via the Investors tab on the company's website.
• 2mo ago AI analysis › Press Release ● Major
Enovis Announces Second Quarter 2026 Results
Enovis reported Q2 2026 sales of $583 million, representing 3% reported growth and 5% organic growth, driven by an 8% reported increase in Reconstructive sales.
Adjusted EBITDA rose to $104 million with a margin of 17.9%, while adjusted EPS reached $0.90, up from $0.72 in the prior year.
The company reaffirmed its full-year 2026 guidance for revenue of $2.31-2.37 billion, adjusted EBITDA of $425-435 million, and adjusted EPS of $3.52-3.73.
• 2mo ago AI analysis › Press Release
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
Enovis announced it will host a conference call on August 6, 2026, to discuss its second quarter 2026 financial results.
The company plans to issue its earnings press release earlier that morning, with the live webcast scheduled to begin at 8:30 a.m. Eastern Time.
Investors can access the event via the Enovis website or by dialing in using the provided conference ID.
• 3mo ago AI analysis › Press Release
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
Enovis announced the U.S. launch of CT-RevitL, a next-generation veterinary PBM laser therapy system developed by its Companion Animal Health division.
The system incorporates COMPASS technology, an intelligent guidance system designed to deliver precise dosing and reduce treatment variability for veterinary teams.
Management noted that the launch reinforces the company's leadership in therapeutic laser technology and supports practice growth by expanding non-drug care offerings.
• 3mo ago AI analysis › Press Release
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
Enovis launched the DonJoy Spinamic Hybrid Scoliosis Brace in the United States, distributed by its subsidiary DJO, LLC.
The hybrid device combines rigid corrective elements with a breathable mesh vest to balance clinical efficacy with patient comfort and wearability.
Available in 10 off-the-shelf sizes, the brace allows for fitting, imaging, and adjustment in a single clinical visit, streamlining workflows for providers.
• 4mo ago AI analysis › Press Release ● Major
Enovis Announces First Quarter 2026 Results
Enovis reported Q1 net sales of $589 million, up 5% on a reported basis and 3% organically, with adjusted EBITDA reaching $104 million.
The Reconstructive segment drove growth with an 11% reported increase, while Prevention & Recovery was flat, resulting in adjusted EPS of $0.89 versus a GAAP loss of $0.15 per share.
The company reaffirmed its full-year 2026 guidance, targeting revenue of $2.31-2.37 billion and adjusted EPS of $3.52-3.73, supported by expectations of 25% or higher free cash flow conversion.
• 5mo ago AI analysis › 
